4d Pharma PLC Pre AGM-Investor Presentation and Q&A
14 6월 2022 - 3:00PM
RNS Non-Regulatory
TIDMDDDD
4d Pharma PLC
14 June 2022
Pre AGM-Investor Presentation and Q&A
Leeds, UK, 14 June 2022 , - 4D pharma plc (AIM: DDDD, Nasdaq
LBPS), a pharmaceutical company leading the development of Live
Biotherapeutic products (LBPs), a novel class of drug derived from
the microbiome, is pleased to announce that Duncan Peyton, Chief
Executive Officer, and John Doyle, Chief Financial Officer, will
provide a live presentation relating to Pre AGM-Investor
Presentation and Q&A via the Investor Meet Company platform on
21st Jun 2022 at 10:00am BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet 4D pharma plc via:
https://www.investormeetcompany.com/4d-pharma-plc/register-investor
Investors who already follow 4D pharma plc on the Investor Meet
Company platform will automatically be invited.
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D pharma has developed a proprietary platform,
MicroRx(R), that rationally identifies Live Biotherapeutics based
on a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with
KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase II clinical
trial of MRx0518 in combination with BAVENCIO(R) (avelumab) in the
first-line maintenance setting for urothelial carcinoma , a Phase I
study of MRx0518 in a neoadjuvant setting for patients with solid
tumors, a Phase I study of MRx0518 in patients with pancreatic
cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix(R)
in irritable bowel syndrome (IBS) which has completed a successful
Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients
with Parkinson's disease is expected to commence in 2022.
Additional preclinical-stage programs include candidates for CNS
disease, immune-inflammatory conditions and cancer. The Company has
a research collaboration with MSD (Merck & Co., Inc.,
Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics
for vaccines.
Contact Information:
4D pharma
Investor Relations ir@4dpharmaplc.com
Singer Capital Markets - Nominated Adviser and Joint Broker
Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496
3000
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker
Dominic Wilson +44 (0)20 7332 2500
Stern Investor Relations
Julie Seidel +1-212-362-1200
julie.seidel@sternir.com
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFJMLTMTTBMRT
(END) Dow Jones Newswires
June 14, 2022 02:00 ET (06:00 GMT)
4d Pharma (LSE:DDDD)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
4d Pharma (LSE:DDDD)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
